Loading...

We've got a brand new version of Simply Wall St! Try it out

Benchmark Botanics

CNSX:BBT
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BBT
CNSX
CA$74M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Benchmark Botanics Inc. cultivates and produces pharmaceutical grade medical and recreational cannabis. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
BBT Share Price and Events
7 Day Returns
0%
CNSX:BBT
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-20.4%
CNSX:BBT
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
BBT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Benchmark Botanics (BBT) 0% 6.2% -24.6% -20.4% - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • BBT outperformed the Pharmaceuticals industry which returned -45.8% over the past year.
  • BBT underperformed the Market in Canada which returned -0.4% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

BBT Value

 Is Benchmark Botanics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Benchmark Botanics. This is due to cash flow or dividend data being unavailable. The share price is CA$0.43.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Benchmark Botanics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Benchmark Botanics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:BBT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.04
CNSX:BBT Share Price ** CNSX (2019-09-19) in CAD CA$0.43
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Benchmark Botanics.

CNSX:BBT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:BBT Share Price ÷ EPS (both in CAD)

= 0.43 ÷ -0.04

-10.15x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Benchmark Botanics is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Benchmark Botanics is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Benchmark Botanics's expected growth come at a high price?
Raw Data
CNSX:BBT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.15x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Benchmark Botanics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Benchmark Botanics's assets?
Raw Data
CNSX:BBT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.09
CNSX:BBT Share Price * CNSX (2019-09-19) in CAD CA$0.43
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:BBT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:BBT Share Price ÷ Book Value per Share (both in CAD)

= 0.43 ÷ 0.09

4.88x

* Primary Listing of Benchmark Botanics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Benchmark Botanics is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Benchmark Botanics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Benchmark Botanics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BBT Future Performance

 How is Benchmark Botanics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Benchmark Botanics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Benchmark Botanics expected to grow at an attractive rate?
  • Unable to compare Benchmark Botanics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Benchmark Botanics's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Benchmark Botanics's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:BBT Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:BBT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:BBT Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -5 -6
2019-03-31 -6 -6
2018-12-31 -5 -6
2018-09-30 -4 -8
2018-06-30 -3 -7
2018-03-31 -2 -5
2017-12-31 -1 -4
2017-09-30 0 -2
2017-06-30 -1
2017-03-31 -1
2016-12-31 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Benchmark Botanics is high growth as no earnings estimate data is available.
  • Unable to determine if Benchmark Botanics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:BBT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Benchmark Botanics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BBT Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.04
2019-03-31 -0.05
2018-12-31 -0.04
2018-09-30 -0.06
2018-06-30 -0.05
2018-03-31 -0.04
2017-12-31 -0.03
2017-09-30 -0.13
2017-06-30 -0.09
2017-03-31 -0.09
2016-12-31 -0.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Benchmark Botanics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Benchmark Botanics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Benchmark Botanics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Benchmark Botanics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Benchmark Botanics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Benchmark Botanics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BBT Past Performance

  How has Benchmark Botanics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Benchmark Botanics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Benchmark Botanics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Benchmark Botanics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Benchmark Botanics's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Benchmark Botanics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Benchmark Botanics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BBT Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.13 -6.16 5.90 0.05
2019-03-31 -6.49 5.92 0.04
2018-12-31 -6.08 5.43 0.04
2018-09-30 -7.86 5.34 0.04
2018-06-30 -6.56 4.02
2018-03-31 -5.17 2.93 0.01
2017-12-31 -4.44 2.25
2017-09-30 -1.56 1.35
2017-06-30 -1.49 1.27
2017-03-31 -1.32 1.10
2016-12-31 -1.18 0.97
2015-12-31 -0.68 0.68

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Benchmark Botanics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Benchmark Botanics has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Benchmark Botanics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Benchmark Botanics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Benchmark Botanics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BBT Health

 How is Benchmark Botanics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Benchmark Botanics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Benchmark Botanics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Benchmark Botanics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Benchmark Botanics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Benchmark Botanics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Benchmark Botanics Company Filings, last reported 2 months ago.

CNSX:BBT Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 15.07 0.00 7.60
2019-03-31 4.83 2.06 0.68
2018-12-31 5.81 0.00 0.33
2018-09-30 7.17 0.00 1.77
2018-06-30 6.06 0.00 1.12
2018-03-31 7.23 0.00 1.86
2017-12-31 7.98 0.00 3.46
2017-09-30 3.07 0.00 0.01
2017-06-30 2.97 0.00 0.05
2017-03-31 3.47 0.00 0.40
2016-12-31 3.47 0.00 0.40
2015-12-31 2.42 0.00
  • Benchmark Botanics has no debt.
  • Benchmark Botanics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Benchmark Botanics has sufficient cash runway for 1.5 years based on current free cash flow.
  • Benchmark Botanics has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 59.7% each year.
X
Financial health checks
We assess Benchmark Botanics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Benchmark Botanics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BBT Dividends

 What is Benchmark Botanics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Benchmark Botanics dividends.
If you bought CA$2,000 of Benchmark Botanics shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Benchmark Botanics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Benchmark Botanics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:BBT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Benchmark Botanics has not reported any payouts.
  • Unable to verify if Benchmark Botanics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Benchmark Botanics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Benchmark Botanics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Benchmark Botanics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Benchmark Botanics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Benchmark Botanics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BBT Management

 What is the CEO of Benchmark Botanics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
William Ying
TENURE AS CEO 0.9 years
CEO Bio

Mr. William Ying has been CEO & Director at Benchmark Botanics, Inc. since October 12 , 2018. Mr. William brings over 20 years of experience in capital markets to the Company. Since 1996 he has served as an investment advisor at various financial institutions including ScotiaMcLeod, Yorkton Securities, Blackmont Capital, Jordan Capital Markets and Mackie Research Capital. Mr. Ying provides growth investment opportunities to accredited investors globally (institutional, corporate and individual) as well as advises growth oriented companies in capital raising, M & A, corporate development and other corporate finance activities. Mr. Ying also participates in the Mentor in Business program at Simon Fraser University (SFU Beedie School of Business) as a mentor to share his business experience with future business leaders. Mr. Ying holds a Masters Degree of Business Administration from Ivey Business School at Western University, Ontario, Canada.

CEO Compensation
  • Insufficient data for William to compare compensation growth.
  • Insufficient data for William to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Benchmark Botanics management team in years:

1.3
Average Tenure
50.5
Average Age
  • The average tenure for the Benchmark Botanics management team is less than 2 years, this suggests a new team.
Management Team

Haifeng Liu

TITLE
President & Director
COMPENSATION
CA$421K
AGE
50
TENURE
1.4 yrs

Johnson Zhang

TITLE
Co-Founder & Director
COMPENSATION
CA$419K
AGE
51

Jin Kuang

TITLE
Interim CFO & Corporate Secretary
COMPENSATION
CA$79K
AGE
48
TENURE
1.3 yrs

Cliff Stowell

TITLE
COO & Director
COMPENSATION
CA$60K
AGE
65
TENURE
1.8 yrs

William Ying

TITLE
CEO & Director
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the Benchmark Botanics board of directors in years:

1.4
Average Tenure
58
Average Age
  • The average tenure for the Benchmark Botanics board of directors is less than 3 years, this suggests a new board.
Board of Directors

George Dorin

TITLE
Chairman
COMPENSATION
CA$4K
AGE
66
TENURE
0.9 yrs

Haifeng Liu

TITLE
President & Director
COMPENSATION
CA$421K
AGE
50
TENURE
1.8 yrs

Johnson Zhang

TITLE
Co-Founder & Director
COMPENSATION
CA$419K
AGE
51
TENURE
1.8 yrs

Cliff Stowell

TITLE
COO & Director
COMPENSATION
CA$60K
AGE
65
TENURE
1.8 yrs

William Ying

TITLE
CEO & Director
TENURE
0.9 yrs

James Moore

TITLE
Director
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
28. Mar 19 Sell George Dorin Individual 28. Mar 19 28. Mar 19 -5,000 CA$0.35 CA$-1,750
31. Jan 19 Sell Claude Stowell Individual 28. Jan 19 28. Jan 19 -250,000 CA$0.45 CA$-112,500
26. Jan 19 Sell George Dorin Individual 23. Jan 19 24. Jan 19 -10,000 CA$0.45 CA$-4,247
03. Jan 19 Sell George Dorin Individual 02. Jan 19 02. Jan 19 -5,000 CA$0.21 CA$-1,050
01. Jan 19 Sell George Dorin Individual 28. Dec 18 28. Dec 18 -5,500 CA$0.23 CA$-1,265
27. Dec 18 Sell George Dorin Individual 20. Dec 18 27. Dec 18 -13,000 CA$0.33 CA$-3,362
20. Dec 18 Sell George Dorin Individual 19. Dec 18 20. Dec 18 -10,000 CA$0.33 CA$-3,311
18. Dec 18 Sell George Dorin Individual 17. Dec 18 18. Dec 18 -10,000 CA$0.32 CA$-3,217
14. Dec 18 Sell George Dorin Individual 13. Dec 18 14. Dec 18 -10,000 CA$0.33 CA$-3,304
07. Dec 18 Sell George Dorin Individual 03. Dec 18 05. Dec 18 -11,500 CA$0.41 CA$-4,336
22. Nov 18 Sell Claude Stowell Individual 21. Nov 18 21. Nov 18 -18,000 CA$0.45 CA$-8,100
21. Nov 18 Sell Claude Stowell Individual 21. Nov 18 21. Nov 18 -11,000 CA$0.45 CA$-4,950
20. Nov 18 Sell Claude Stowell Individual 20. Nov 18 20. Nov 18 -9,000 CA$0.45 CA$-4,050
09. Nov 18 Sell George Dorin Individual 07. Nov 18 08. Nov 18 -20,000 CA$0.45 CA$-8,837
31. Oct 18 Sell Claude Stowell Individual 31. Oct 18 31. Oct 18 -9,000 CA$0.49 CA$-4,410
26. Oct 18 Sell Claude Stowell Individual 23. Oct 18 23. Oct 18 -1,000 CA$0.49 CA$-490
03. Oct 18 Sell Claude Stowell Individual 03. Oct 18 03. Oct 18 -10,000 CA$0.55 CA$-5,500
02. Oct 18 Sell Claude Stowell Individual 02. Oct 18 02. Oct 18 -10,000 CA$0.58 CA$-5,800
X
Management checks
We assess Benchmark Botanics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Benchmark Botanics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BBT News

Simply Wall St News

Benchmark Botanics Inc. (CNSX:BBT) Insiders Have Been Selling

Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. … In total, Benchmark Botanics insiders sold more than they bought over the last year … It is certainly not great to see that insiders have sold shares in the company

Simply Wall St -

Could Benchmark Botanics Inc.'s (CNSX:BBT) Investor Composition Influence The Stock Price?

A look at the shareholders of Benchmark Botanics Inc. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Benchmark Botanics is a smaller company with a market capitalization of CA$47m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Should You Be Concerned About Benchmark Botanics Inc's (CNSX:BBT) Shareholders?

I am going to take a deep dive into Benchmark Botanics Inc’s (CNSX:BBT) most recent ownership structure, not a frequent subject of discussion among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

BBT Company Info

Description

Benchmark Botanics Inc. cultivates and produces pharmaceutical grade medical and recreational cannabis. The company is headquartered in Richmond, Canada.

Details
Name: Benchmark Botanics Inc.
BBT
Exchange: CNSX
Founded:
CA$73,592,605
171,145,594
Website: http://www.benchmarkbotanics.com
Address: Benchmark Botanics Inc.
6111 London Road,
Suite 105,
Richmond,
British Columbia, V7E 3S3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX BBT Common Shares Canadian National Stock Exchange CA CAD 03. Nov 2017
OTCPK BHHK.F Common Shares Pink Sheets LLC US USD 03. Nov 2017
DB BBW Common Shares Deutsche Boerse AG DE EUR 03. Nov 2017
Number of employees
Current staff
Staff numbers
0
Benchmark Botanics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:26
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/08/28
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.